A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Dupixent peak sales ambition raised to more than €13 billion
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
It recognizes the company's commitment to safeguarding sensitive data, protecting patient information
Vault PromoMats helps life sciences companies speed the creation, review, and distribution of compliant content. Built-in digital asset management enables content reuse and reduces spend on promotional materials
Subscribe To Our Newsletter & Stay Updated
